ZYNTEGLO betibeglogene autotemcel (shorter name: beti-cel) was jointly assessed as a Beneluxa pilot. The HTA process was carried out simultaneously in Amsterdam (ZIN) and Brussels (RIZIV-INAMI). The…
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Beneluxa statement: award of contract to supply the International Horizon Scanning Database
We are delighted to share that today the International Horizon Scanning Initiative - IHSI - has made a major step forward in securing development of the international horizon scanning database which…
Short Statement on Alzheimer’s HTA
The Beneluxa group is following with attention the therapies relative to Alzheimer’s disease coming to the market. Recently the FDA in the US approved an anti-amyloid antibody amid some controversy;…